monalizumab
Showing 1 - 9 of 9
Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Durvalumab
- +3 more
- (no location specified)
Jun 5, 2023
SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor Trial in France (Autophagy inhibitor
Completed
- SARS-CoV-2 (COVID-19) Infection
- Advanced or Metastatic Hematological or Solid Tumor
- Autophagy inhibitor (GNS651)
- +3 more
-
Lyon, Rhône, France
- +11 more
Sep 29, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (Monalizumab, Cetuximab)
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Monalizumab
- Cetuximab
-
Tucson, Arizona
- +126 more
Oct 21, 2022
NSCLC Trial in Worldwide (Durvalumab, Oleclumab, Monalizumab)
Recruiting
- Non-Small Cell Lung Cancer
- Durvalumab
- +3 more
-
San Diego, California
- +197 more
Oct 11, 2022
Resectable, Early-stage, NSCLC Trial in Worldwide (Durvalumab, Oleclumab, Monalizumab)
Chronic Lymphocytic Leukemia Trial in Columbus (monalizumab)
Terminated
- Chronic Lymphocytic Leukemia
- monalizumab
-
Columbus, OhioThe Ohio State University Wexner Medical Center
Dec 4, 2019
Hematologic Malignancies Trial in Marseille (Monalizumab)
Unknown status
- Hematologic Malignancies
- Monalizumab
-
Marseille, Bouches Du Rhônes, FranceInstitut Paoli Calmettes
Sep 18, 2018
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus Trial
Withdrawn
- Adenocarcinoma of the Esophagus
- +2 more
- Monalizumab
- +4 more
-
Brussels, BelgiumInstitut Jules Bordet
Dec 18, 2017